| abstract |
The present application describes a compound or enantiomers, stereoisomers, rotameres, tautomers, racemates or prodrugs of said compound or one of its pharmaceutically acceptable salts, solvates or esters or of said prodrug, said compound having the general structure disclosed in Formula 1: ( see Formula 1) and its pharmaceutically acceptable salts, solvates or esters; A method for treating chemokine-mediated diseases is also described, such as palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting examples include psoriasis), autoimmune diseases (non-limiting examples include rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting examples include rejection or allografts, rejection of xenografts), infectious diseases (for example, tuberculoid leprosy), rashes against fixed drugs, delayed cutaneous hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors, using a compound of Formula 1. |